Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.41 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619689 | 0.76 | POLB (0.35) | ALDH1A1MAPTHTTKMT2ASMN1; SMN2 | |
| SCHEMBL16431949 | 0.73 | — | — | |
| SCHEMBL18883779 | 0.73 | — | — | |
| SCHEMBL13341452 | 0.73 | — | — | |
| SCHEMBL8068305 | 0.72 | ESR1 (0.40) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL18116993 | 0.72 | ESR1 (0.41) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL19661200 | 0.69 | ESR1 (0.42) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL13019256 | 0.69 | ESR1 (0.42) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL18117012 | 0.69 | ESR1 (0.37) | ESR1HSP90AA1MMP3CHRM1TBXA2R | |
| SCHEMBL18116961 | 0.68 | ESR1 (0.41) | ESR1HSP90AA1MMP3CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883628-B1 | 17BETA-(2-OXO-TETRAHYDROFURAN-4-YL)-THIO-ANDROSTANE DERIVATIVES (17BETA-(GAMMA-BUTYRIC ACID LACTONE)-THIO DERIVATIVES) FOR THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS AND A PROCESS FOR THE PRODUCTION THEREOF | GLAXO GROUP LTD (GB) | 2000-08-16 | — | — | EP | claimed |
| EP-0883628-A1 | 17BETA-(2-OXO-TETRAHYDROFURAN-4-YL)-THIO-ANDROSTANE DERIVATIVES (17BETA-(GAMMA-BUTYRIC ACID LACTONE)-THIO DERIVATIVES) FOR THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS AND A PROCESS FOR THE PRODUCTION THEREOF | GLAXO GROUP LIMITED (GB) | 1998-12-16 | — | — | EP | claimed |
| US-5801165-A | Antiinflammatory, immunosuppressive and antialleric 16, 17-alkylidioxy-steroids | RHONE-POULENC RORER LIMITED (GB) | 1998-09-01 | — | — | US | claimed |
| WO-1997024368-A1 | 17BETA-(2-OXO-TETRAHYDROFURAN-4-YL)-THIO-ANDROSTANE DERIVATIVES (17BETA-(GAMMA-BUTYRIC ACID LACTONE)-THIO DERIVATIVES) FOR THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS AND A PROCESS FOR THE PRODUCTION THEREOF | GLAXO GROUP LIMITED (GB) | 1997-07-10 | — | — | WO | claimed |
| EP-0675897-B1 | NEW STEROIDS | RHONE POULENC RORER LTD (GB) | 1997-06-18 | — | — | EP | claimed |
| EP-0675897-A1 | NEW STEROIDS. | RHONE POULENC RORER LTD (GB) | 1995-10-11 | — | — | EP | claimed |
| WO-1994014834-A1 | NEW STEROIDS | RHONE-POULENC RORER LIMITED (GB) | 1994-07-07 | — | — | WO | claimed |
| US-10669290-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-9828391-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9771382-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-09-26 | — | — | US | disclosed |
| US-6114318-A | ANTIINFLAMMATORY AGENT, ANTIALLERGENS | GLAXO GROUP LIMITED (GB) | 2000-09-05 | — | — | US | disclosed |
| EP-0883628-B1 | 17BETA-(2-OXO-TETRAHYDROFURAN-4-YL)-THIO-ANDROSTANE DERIVATIVES (17BETA-(GAMMA-BUTYRIC ACID LACTONE)-THIO DERIVATIVES) FOR THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS AND A PROCESS FOR THE PRODUCTION THEREOF | GLAXO GROUP LTD (GB) | 2000-08-16 | — | — | EP | disclosed |
| EP-0675897-B1 | NEW STEROIDS | RHONE POULENC RORER LTD (GB) | 1997-06-18 | — | — | EP | disclosed |
| EP-0675897-A1 | NEW STEROIDS. | RHONE POULENC RORER LTD (GB) | 1995-10-11 | — | — | EP | disclosed |
| US-5453502-A | 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes for preparation thereof | ELI LILLY AND COMPANY (US) | 1995-09-26 | — | — | US | disclosed |
| EP-0672656-A1 | 1,3,4 substituted and bicyclic derivatives of 2-azetidinones and processes for preparation thereof | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994014834-A1 | NEW STEROIDS | RHONE-POULENC RORER LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
| US-5037975-A | Antibiotics | ELI LILLY AND COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-4939249-A | HEATING CEPHALOSPORIN 1,1-DIOXIDE IN SOLVENT WITH FREE RADICAL INITIATOR | ELI LILLY AND COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | ESR1 1864/4885HSP90AA1 2092/4885MMP3 321/4885 |
| US-10669290-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | ESR1 1864/4885HSP90AA1 2092/4885MMP3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.